Puma Biotechnology Announces Positive Top Line Results From Phase III PB272 Trial In Adjuvant Breast Cancer

By: via Benzinga
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced top line results from the Phase III ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.